Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.52 |
| ▸ | CETP | P11597 | 6/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7175726 | 1.00 | PPARA (0.52) | PPARACETPPLK1CA12CA1 | |
| SCHEMBL7176997 | 1.00 | PPARA (0.52) | PPARACETPPLK1CA12CA1 | |
| SCHEMBL7183088 | 1.00 | PPARA (0.52) | PPARACETPPLK1CA12CA1 | |
| SCHEMBL7175425 | 0.99 | PPARA (0.50) | PPARACETPPLK1CA12CA1 | |
| SCHEMBL7185424 | 0.95 | PPARA (0.48) | PPARAPLK1CA12CA1CA2 | |
| SCHEMBL7189220 | 0.92 | PPARA (0.47) | PPARACETPPLK1CA12CA1 | |
| SCHEMBL7190145 | 0.92 | PPARA (0.47) | PPARACETPPLK1CA12CA1 | |
| SCHEMBL7179711 | 0.92 | PPARA (0.47) | PPARACETPPLK1CA12CA1 | |
| SCHEMBL7188932 | 0.92 | PPARA (0.47) | PPARACETPPLK1CA12CA1 | |
| SCHEMBL7188137 | 0.90 | PPARA (0.45) | PPARACETPPLK1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1200943-C | Organometallic acyl-aryl phosphine | CIBA SC HOLDING AG (CH) | 2005-05-11 | — | — | CN | disclosed |
| US-6579663-B2 | Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020107413-A1 | Organometallic monoacylarylphosphines | WOLF JEAN-PIERRE (CH) | 2002-08-08 | — | — | US | disclosed |
| US-6399805-B2 | SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES | CIBA SPECIALTY CHEMICALS CORPORATION | 2002-06-04 | — | — | US | disclosed |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | CIBA SPECIALTY CHEMICALS CORP. | 2001-10-18 | — | — | US | disclosed |
| CN-1308081-A | Organometallic acyl-aryl phosphine | CIBA SC HOLDING AG (CH) | 2001-08-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107413-A1 | Organometallic monoacylarylphosphines | CBR1, NAF1, DHCR24 | PPARA 3039/4885CETP 750/4885PLK1 2655/4885 |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | NAF1, DHCR24, CBR1 | PPARA 2624/4885CETP 526/4885PLK1 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.